Cybersecurity in Medical Devices (2026): Quality Management System Considerations and FDA Premarket Submission Expectations Explained
Understanding Regulatory Intent, Risk-Based Cybersecurity Assurance, and Practical Implications for Medical Device & IVD Software Manufacturers
Introduction
What FDA Says
FDA’s February 2026 guidance, Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions, provides updated recommendations for managing cybersecurity risks throughout the device lifecycle. The document outlines expectations for secure product design, risk management, documentation, and submission content necessary to demonstrate that cybersecurity risks have been adequately addressed.
FDA’s Intent
FDA is signaling a shift from treating cybersecurity as a technical afterthought toward treating it as a core quality and safety function. The Agency is emphasizing that cybersecurity is inseparable from device performance, patient safety, and data integrity — and therefore must be embedded within the Quality Management System (QMS).
FDA appears to recognize that many manufacturers still rely on fragmented or reactive cybersecurity practices. The intent is to push industry toward proactive, risk‑based cybersecurity assurance aligned with modern threats, modern architectures, and modern regulatory expectations.
Examples
Cybersecurity expectations apply to devices and software such as:
- Connected medical devices (wired or wireless)
- Software as a Medical Device (SaMD)
- Embedded device firmware
- Cloud‑connected IVD platforms
- Mobile medical applications
- Companion apps and remote monitoring tools
Inspection Implications
Inspectors may expect firms to explain:
- How cybersecurity risk management is integrated into the QMS
- How cybersecurity controls were selected and justified
- How cybersecurity testing demonstrates confidence in secure performance
- How cybersecurity considerations influenced design, architecture, and documentation
Organizations that treat cybersecurity as a documentation exercise rather than a risk‑based assurance activity may struggle to defend their approach.
Background
What FDA Says
The guidance describes the evolution of cybersecurity expectations and the increasing need for robust, lifecycle‑based cybersecurity practices. FDA highlights the growing sophistication of threats, the expanding attack surface of connected devices, and the importance of maintaining device safety in the presence of cybersecurity risks.
FDA’s Intent
FDA appears to be acknowledging that cybersecurity threats evolve faster than traditional device development cycles. The Agency recognizes that legacy approaches — such as static risk assessments or one‑time penetration tests — are insufficient for modern connected systems.
The intent is to encourage manufacturers to adopt continuous, risk‑based cybersecurity assurance practices that align with current threat landscapes and modern engineering methods.
Examples
Challenges under legacy cybersecurity programs include:
- One‑time penetration tests that do not reflect ongoing threats
- Overreliance on vendor claims without independent verification
- Incomplete threat modeling
- Insufficient documentation of cybersecurity design decisions
- Slow or inconsistent patching processes
Inspection Implications
Inspectors may look for evidence that cybersecurity activities are:
- Current
- Risk‑based
- Justified
- Integrated into design controls and QMS processes
Organizations should be able to explain why cybersecurity decisions were made — not merely present documentation.
III. Scope
What FDA Says
The guidance applies to all medical devices containing software, including SaMD, SiMD, and connected IVD systems. It also applies to cybersecurity processes embedded within the QMS, such as risk management, design controls, CAPA, and postmarket surveillance.
FDA’s Intent
FDA is clarifying that cybersecurity is not limited to “connected devices.” Any device containing software — even if not networked — may present cybersecurity risks that affect safety or performance.
The Agency appears to be encouraging manufacturers to evaluate cybersecurity based on intended use and potential impact, not on whether the device is cloud‑connected or internet‑enabled.
Examples
Systems within scope include:
- SaMD diagnostic platforms
- IVD cloud analytics systems
- Implantable devices with wireless telemetry
- Home‑use connected devices
- Mobile apps used for device control
- Laboratory automation software
Inspection Implications
Inspectors may question inconsistencies in how cybersecurity is applied across similar device types. Firms should have a defensible rationale for determining which cybersecurity activities apply to each product.
Definitions
What FDA Says
The guidance provides definitions for key cybersecurity concepts such as threat, vulnerability, exploitability, security control, and security risk.
FDA’s Intent
FDA is establishing a common vocabulary to reduce misinterpretation and ensure consistent application of cybersecurity principles across industry.
The Agency appears to recognize that inconsistent terminology leads to inconsistent cybersecurity practices.
Examples
Foundational terms include:
- Threat — potential cause of an unwanted cybersecurity event
- Vulnerability — weakness that could be exploited
- Security control — measure to reduce cybersecurity risk
- Exploitability — likelihood a vulnerability can be exploited
Inspection Implications
Inspectors may expect terminology used in risk assessments, design documentation, and submission materials to align with FDA definitions. Consistent vocabulary demonstrates organizational maturity.
Cybersecurity Risk Management
What FDA Says
FDA describes cybersecurity risk management as a lifecycle process integrated into design controls, risk management, and QMS activities. Manufacturers must identify threats, assess vulnerabilities, evaluate exploitability, and implement controls that reduce risk to an acceptable level.
FDA’s Intent
This is the central message of the guidance.
FDA is attempting to shift organizations away from treating cybersecurity as a technical checklist and toward treating it as a risk‑based assurance activity focused on safety, performance, and data integrity.
The Agency appears to be emphasizing confidence in secure performance rather than compliance through documentation volume.
Examples
Cybersecurity evidence may include:
- Threat modeling outputs
- Vulnerability assessments
- Penetration testing results
- Secure design documentation
- Patch management plans
- Software bill of materials (SBOM)
- Cryptographic control justification
Inspection Implications
Inspectors may focus on whether cybersecurity activities demonstrate that the device is acceptably secure for its intended use. The rationale for cybersecurity decisions may be more important than the quantity of documentation.
Cybersecurity Risk Framework
What FDA Says
FDA presents a risk framework that evaluates cybersecurity impact on device safety, performance, data integrity, and clinical functionality.
FDA’s Intent
FDA is encouraging firms to direct cybersecurity resources toward areas where exploitation could affect patient safety, diagnostic accuracy, or regulatory compliance.
The Agency appears to be discouraging uniform cybersecurity strategies that treat all threats equally regardless of impact.
Examples
Higher‑impact cybersecurity risks include:
- Unauthorized modification of device parameters
- Manipulation of diagnostic outputs
- Interruption of therapy delivery
- Corruption of clinical data
Lower‑impact risks include:
- Cosmetic UI issues
- Non‑clinical data exposure
- Logging inconsistencies
Inspection Implications
Inspectors may expect a clear connection between:
- Threat modeling
- Risk evaluation
- Security control selection
- Objective evidence
Weak connections may indicate gaps in cybersecurity assurance.
Intended Use and Cybersecurity
What FDA Says
FDA identifies intended use as foundational to cybersecurity risk assessment. Cybersecurity decisions must be tied to how the device is used, by whom, and in what environment.
FDA’s Intent
FDA wants organizations to understand device purpose before determining cybersecurity risk or selecting controls. Intended use drives threat modeling, exploitability assessment, and control justification.
Examples
Intended use statements may describe:
- Clinical environment
- User roles
- Connectivity requirements
- Data flows
- Safety‑critical functions
Inspection Implications
Inspectors may examine whether cybersecurity activities trace back to clearly defined intended use statements. Weak or generic intended use statements may undermine cybersecurity risk assessments.
Cybersecurity Testing and Assurance Activities
What FDA Says
FDA states that cybersecurity testing should be appropriate for the device’s intended use and associated risk. Testing may include penetration testing, vulnerability scanning, code analysis, and security control verification.
FDA’s Intent
FDA is introducing flexibility in how cybersecurity assurance may be accomplished. The Agency appears to be making clear that meaningful evidence can be generated through various approaches, not solely through traditional penetration testing.
Examples
Potential assurance activities include:
- Threat‑based penetration testing
- Secure code review
- Vulnerability scanning
- Cryptographic control verification
- Authentication/authorization testing
- SBOM‑based vulnerability analysis
Inspection Implications
Inspectors may focus on whether chosen activities were suitable for establishing confidence in secure performance rather than whether a particular testing methodology was used.
Cybersecurity Documentation and Premarket Submissions
What FDA Says
FDA outlines required cybersecurity documentation for premarket submissions, including threat models, risk assessments, SBOMs, testing evidence, and security architecture descriptions.
FDA’s Intent
FDA is attempting to separate documentation quality from documentation quantity. The Agency wants submission materials that clearly explain cybersecurity decisions, controls, and evidence — not excessive or redundant documentation.
Examples
Submission documentation may include:
- Cybersecurity risk management report
- Threat modeling summary
- SBOM
- Secure design documentation
- Testing protocols and results
- Patch and update strategy
- Labeling and user instructions
Inspection Implications
Inspectors and reviewers will evaluate whether documentation provides a coherent and defensible explanation of cybersecurity assurance. Well‑structured records should allow an independent reviewer to understand the basis for confidence in secure performance.
Conclusion: What This Means for Medical Device & IVD Software Manufacturers
FDA’s 2026 cybersecurity guidance represents a clear regulatory shift: cybersecurity is now a core quality function, not a technical add‑on. Manufacturers must demonstrate that cybersecurity risks have been identified, evaluated, controlled, and documented in a way that aligns with modern threats and modern regulatory expectations.
Organizations that adopt a risk‑based, lifecycle‑driven cybersecurity assurance program will be better positioned for inspections, submissions, and long‑term product safety.
This article is for general informational purposes and does not constitute legal or regulatory advice.